



VMRD

PO Box 502, Pullman, WA 99163 USA

Telephone: 509-334-5815

Fax: 509-332-5356

E-mail: vmrd@vmrd.com

Web site: <http://www.vmrd.com>

Certificate of Analysis

**EQUINE
RHINOPNEUMONITIS
VIRUS/EQUINE
HERPESVIRUS TYPE 1**

Anti-Viral Antiserum

CATALOG NO.: 210-70-ERV
re-order as PAB-ERV


VOLUME: 1 ml

LOT: P081121-005

EXPIRATION: 25 April 2016

VIRUS: Equine Rhinopneumonitis
Virus/Equine Herpesvirus Type 1
(ERV/EHV-1)

ERV/EHV-1 Antisera @1/400
P081121-005 400X



DESCRIPTION: Anti-ERV/EHV-1 polyclonal antiserum. Caprine origin.

QUALITY CONTROL METHOD: Indirect FA using EHV-1 12-well substrate slide (catalog no. SLD-IFA-ERV); VMRD Anti-Caprine IgG FITC conjugate (catalog no. CJ-F-CAPG-1ML or 10ML).

Specific Reaction: 3-4+ fluorescence at 1/400 with an endpoint titer = 1/8000.

Other Comments: The Antiserum has also been screened by Indirect FA and does not react with equine arteritis virus (EAV) or equine infectious anemia virus (EIAV).

INTENDED USE: Useful for IFA. Not suitable for cell culture serum neutralization because it contains sodium azide.

STORAGE: This antiserum is provided in liquid form and should be stored at 2-7°C. **DO NOT FREEZE!** If antiserum becomes cloudy, it should be discarded. This antiserum contains 0.09% sodium azide as a preservative.

FOR *IN VITRO* LABORATORY USE ONLY.

WARRANTY: VMRD, Inc. warrants that this product is as described in the quantity and contents stated on the label at the time of delivery to the customer. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE MADE BEYOND THE LABEL DESCRIPTION, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE. Remedy is limited to replacement of the product or refund of the purchase price. VMRD, Inc. is not liable for property damage, personal injury, or economic loss caused by the product. The information listed in this information sheet is provided for reference only, and should not be substituted for the user's own incoming material quality control.

H:\Quality VMRD\QC\CofA\Antisera\ERV\PAB-ERV_P081121-005_160425(Revised).doc
10 September 2013